[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • Organomegaly, skin involvement, circulating atypical lymphocytes ("flower" cells) with a CD4+ CD25+ phenotype and hypercalcaemia are the most common disease features.
  • The diagnosis should be based on a constellation of clinical features and laboratory investigations.
  • The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I.
  • The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sézary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease.
  • The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms.
  • Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas.
  • The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate.
  • Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunophenotyping. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


2. Dearden C, Matutes E, Catovsky D: Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Williston Park); 2000 Jun;14(6 Suppl 2):37-40
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin treatment of cutaneous T-cell lymphoma.
  • Mycosis fungoides is an indolent primary cutaneous T-cell lymphoma (CTCL) that usually progresses from localized skin lesions to systemic disease.
  • The malignant cell in both diseases is a mature T cell, usually with a CD4-positive, CD8-negative phenotype.
  • Among the treatment modalities used in these diseases are skin-directed therapy, single-agent and combination systemic chemotherapy, and, more recently, bioimmunotherapy.
  • At The Royal Marsden Hospital, we treated 29 cutaneous T-cell lymphoma patients with pentostatin, including 16 with Sézary syndrome, 5 with mycosis fungoides, and 8 with other cutaneous T-cell lymphomas.
  • The majority (N = 20) had received prior therapy.
  • There was no significant treatment-related toxicity.
  • We conclude that pentostatin is an effective single-agent therapy for patients with Sézary syndrome but not for those with other cutaneous T-cell lymphomas.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Lymphoma, T-Cell / drug therapy. Pentostatin / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mycosis Fungoides / drug therapy. Sezary Syndrome / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887643.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


3. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH: Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest Dermatol; 2002 Feb;118(2):366-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
  • Cutaneous T cell lymphoma is a clonally derived, skin-invasive malignancy of CD4+ T lymphocytes with the phenotype of mature helper T cells.
  • Previous work has demonstrated that the Sézary form, or typically leukemic form of cutaneous T cell lymphoma, is characterized by prominent immunologic defects, including depressed cell-mediated immunity associated with marked defects in the production of interleukin-12 and other type 1 helper T cell cytokines.
  • Recent clinical trials with recombinant human interleukin-12 for cutaneous T cell lymphoma have demonstrated that it is a potent therapeutic agent, which induces cytotoxic T cell responses.
  • In an effort to enhance the overall response rate and to overcome the refractoriness to recombinant human interleukin-12 therapy, we studied the immunologic effects in vitro of adding interleukin-2 to interleukin-12 as a model to achieve these goals.
  • We examined the stimulation of interferon-gamma production, natural killer cell activity and interleukin-12 receptor expression by T cells of cutaneous T cell lymphoma patients.
  • The addition of interleukin-12 to cutaneous T cell lymphoma patient peripheral blood cells resulted in the production of interferon-gamma (mean = 7914 pg per ml +/- 2161, n = 15) as did interleukin-2 alone (mean = 7222 pg per ml +/- 2228, n = 15).
  • Similarly, addition of interleukin-2 to interleukin-12 synergistically enhanced both the natural killer cell activity of 15 cutaneous T cell lymphoma patients as well as T cell surface interleukin-12 receptor expression in comparison with the effects of interleukin-12 or interleukin-2 alone.
  • Thus, interleukin-2 plus interleukin-12 unequivocally produces the synergistic enhancement of multiple parameters of cell-mediated immunity as well as upmodulating interleukin-12 receptor expression; this indicates that protocols combining these two potent immune enhancing cytokines may have added therapeutic benefit for cutaneous T cell lymphoma.
  • [MeSH-major] Immunity, Cellular / drug effects. Immunologic Factors / therapeutic use. Interleukin-12 / therapeutic use. Interleukin-2 / therapeutic use. Sezary Syndrome / drug therapy. Sezary Syndrome / immunology
  • [MeSH-minor] Drug Synergism. Drug Therapy, Combination. Humans. Interferon-gamma / biosynthesis. Killer Cells, Natural / drug effects. Killer Cells, Natural / physiology. Monocytes / metabolism. Receptors, Interleukin / metabolism. Receptors, Interleukin-12. T-Lymphocytes / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841558.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 10815
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-12; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


Advertisement
4. Shapiro M, Wasik MA, Junkins-Hopkins JM, Rook AH, Vittorio CC, Itakura H, Frankel MC, Georgala S, Schuster SJ: Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol; 2003 Sep;74(1):46-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
  • Although its cell of origin is still controversial, the blastic NK-cell leukemia/lymphoma clearly represents a distinct type of hematopoietic neoplasm that is particularly clinically aggressive when it occurs in elderly patients as a disseminated, multi-organ disease.
  • Consistently effective treatments have not been developed for this malignancy.
  • The present report describes two elderly patients with widespread blastic NK-cell leukemia/lymphoma involving the skin, bone marrow, peripheral blood, lymph nodes, and viscera.
  • In both cases the malignant cells were CD56+, CD2+, and terminal deoxynucleotidyl transferase (TdT) positive with no detectable T-cell receptor (TCR) gamma chain gene rearrangement.
  • The above findings support the precursor NK-cell, rather than mature NK- or non-NK-cell, origin of the malignant cells.
  • It is noteworthy that the two patients achieved complete responses to treatment with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with high-dose methotrexate/cytarabine, a regimen currently utilized in acute lymphoblastic leukemia and high-grade lymphoma.
  • The complete remission (CR) was sustained for 24 months in one patient who received four cycles (eight courses) of the treatment.
  • If similar results are obtained with future patients, a randomized study comparing the hyper-CVAD regimen to other therapeutic strategies may be warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Killer Cells, Natural / pathology. Leukemia / drug therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12949889.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA89194
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


5. Rezania D, Sokol L, Cualing HD: Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control; 2007 Apr;14(2):112-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin.
  • Two major competing classifications were the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC).
  • The principal authors met for a consensus meeting resulted in a combined classification called WHO-EORTC Classification of Cutaneous Lymphoma.
  • METHODS: We review the classification of "mature" or peripheral T-cell lymphoma (PTCL) with high predilection to the skin as published by the WHO-EORTC.
  • Finally, the salient findings are compared with similar-looking nodal PTCLs with a high frequency of skin involvement.
  • Changes from the previous classifications are discussed, and the rare group of nodal PTCLs with high predilection to the skin are presented.
  • The salient findings, diagnostic features, and treatments are included, along with summary tables and clinical-histopathologic images.
  • CONCLUSIONS: This review may serve as a guide for hematologists, oncologists and dermatologists in the diagnosis and management of these rare, aggressive, and often difficult to diagnose lymphomas.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell, Peripheral / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. CD4-Positive T-Lymphocytes. CD8-Positive T-Lymphocytes. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387296.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 65
  •  go-up   go-down


6. Knol AC, Quéreux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, Dréno B: Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Exp Dermatol; 2010 Aug;19(8):e95-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders, characterized by the infiltration of the epidermis by mature and activated malignant CD4+ T-lymphocytes.
  • Retinoids such as retinoic acid and synthetic analogues have long been used alone or in combination with other therapies for CTCL.
  • Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy.
  • Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease despite improvement of cutaneous signs and symptoms were reported.
  • We found that the frequency of CD4+CD25(high) Treg cells was not significantly different before starting bexarotene and after 6 months of treatment in CTCL patients.
  • However, we observed that the frequency of CD4+CD25(high) Treg cells before the beginning of the treatment was significantly increased compared to healthy donors.
  • In addition, functional assays demonstrated that Foxp3 expressing CD4+CD25(high) T-cells were capable of suppressing autologous CD4 + CD25- T-cell proliferation.
  • The treatment with bexarotene does not seem to affect the regulatory T-cell compartment.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Interleukin-2 Receptor alpha Subunit / metabolism. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. T-Lymphocytes, Regulatory / pathology. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Aged. Anticarcinogenic Agents / pharmacology. Anticarcinogenic Agents / therapeutic use. Case-Control Studies. Cell Proliferation / drug effects. Female. Forkhead Transcription Factors / metabolism. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Transforming Growth Factor beta1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845755.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Tetrahydronaphthalenes; 0 / Transforming Growth Factor beta1; 130068-27-8 / Interleukin-10; A61RXM4375 / bexarotene
  •  go-up   go-down


7. Crovetti G, Carabelli A, Berti E, Guizzardi M, Fossati S, De Filippo C, Bertani E: Photopheresis in cutaneous T-cell lymphoma: five-year experience. Int J Artif Organs; 2000 Jan;23(1):55-62
Hazardous Substances Data Bank. 8-METHOXYPSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photopheresis in cutaneous T-cell lymphoma: five-year experience.
  • BACKGROUND: Cutaneous T-cell lymphoma (CTCL) includes several lymphoproliferative disorders involving mature T-lymphocyte proliferation initially confined to the cutis.
  • The therapy of CTCL depends on the stage of the disease and the patient's general conditions.
  • For advanced cases it includes chemotherapy, retinoids, and interferon-alpha.
  • Since 1987 extracorporeal photochemotherapy (ECP), a novel immunomodulatory approach based on apheresis and photoirradiation of leukocytes, has been successfully introduced for the treatment of advanced CTCL.
  • Five of the six patients given IFN-alpha as adjunctive therapy had a PR and one a CR.
  • Four patients are in CR without therapy at follow-ups of 46, 20, 10 and 8 months.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / drug therapy. Photopheresis / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Interferon-alpha / therapeutic use. Male. Methoxsalen / therapeutic use. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12118838.001).
  • [ISSN] 0391-3988
  • [Journal-full-title] The International journal of artificial organs
  • [ISO-abbreviation] Int J Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


8. Choi J, Foss F: Cutaneous T-cell lymphoma: Biologic targets for therapy. Curr Hematol Malig Rep; 2007 Oct;2(4):272-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous T-cell lymphoma: Biologic targets for therapy.
  • Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes.
  • In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines.
  • In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation.
  • Each of these steps in disease pathogenesis offers a potential object for targeted therapies.
  • This article reviews the recent research into the design and use of targeted therapies for CTCL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antigens, CD4 / drug effects. Apoptosis / drug effects. Clinical Trials as Topic. Diphtheria Toxin / therapeutic use. Drug Delivery Systems. Drug Design. Epigenesis, Genetic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunologic Factors / therapeutic use. Immunotherapy. Interferon-gamma / therapeutic use. Interleukin-2 / therapeutic use. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Photopheresis. Recombinant Fusion Proteins / therapeutic use. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / metabolism. T-Lymphocyte Subsets / pathology. Tumor Escape / drug effects

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):438-47 [11251964.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Nat Rev Immunol. 2006 Nov;6(11):836-48 [17063185.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] J Am Acad Dermatol. 1995 Mar;32(3):448-53 [7868714.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):516-23 [12872134.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):146-60 [17275192.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):553-63 [15627017.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1477-88 [12782714.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Oct;9(5):1057-76 [8522484.001]
  • [Cites] J Invest Dermatol. 1996 Sep;107(3):392-7 [8751976.001]
  • [Cites] JAMA. 1992 Mar 11;267(10):1354-8 [1740857.001]
  • [Cites] Blood. 2006 May 15;107(10):4030-8 [16418328.001]
  • [Cites] J Invest Dermatol. 2002 Mar;118(3):493-9 [11874489.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;941:1-11 [11594563.001]
  • [Cites] Arch Dermatol. 1998 Aug;134(8):949-54 [9722724.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4142-9 [15328153.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1978-88 [15128898.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2440-5 [16322477.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1435-48, ix [14710894.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):894-901 [14632210.001]
  • [Cites] J Invest Dermatol. 1999 Mar;112(3):317-21 [10084308.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):464-75 [12207585.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):798-812 [15841167.001]
  • [Cites] Blood. 2005 Jul 15;106(2):454-7 [15811959.001]
  • [Cites] Blood. 1999 Aug 1;94(3):902-8 [10419880.001]
  • [Cites] Br J Dermatol. 2004 Sep;151(3):546-56 [15377339.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2005 Oct;21(5):260-6 [16149939.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1054-60 [12164743.001]
  • [Cites] Yale J Biol Med. 1989 Nov-Dec;62(6):595-609 [2636801.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23 (17 ):3886-96 [15897551.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):107-17 [12084452.001]
  • [Cites] J Photochem Photobiol B. 1995 Aug;29(2-3):193-8 [7472813.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2929-39 [11929784.001]
  • [Cites] Cell Cycle. 2004 May;3(5):534-5 [15020838.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Dermatol Ther. 2003;16(4):337-46 [14686977.001]
  • (PMID = 20425380.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Immunologic Factors; 0 / Interleukin-2; 0 / Neoplasm Proteins; 0 / Recombinant Fusion Proteins; 0 / zanolimumab; 25E79B5CTM / denileukin diftitox; 82115-62-6 / Interferon-gamma
  • [Number-of-references] 41
  •  go-up   go-down


9. Dearden C: Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm; 2004 Aug;19(4):391-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in peripheral T-cell malignancies.
  • Over the past 5 years, a number of trials have demonstrated that alemtuzumab has clinical activity in mature T-cell diseases such as T-cell prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma (CTCL).
  • In heavily pretreated relapsed/refractory patients alemtuzumab induced responses in more than two thirds of T-PLL and more than 50% of CTCL patients.
  • Alemtuzumab is particularly effective in clearing malignant lymphocytes from peripheral blood and bone marrow and may therefore facilitate stem-cell transplantation (SCT) in selected patients.
  • The toxicity profile for the antibody is acceptable; the major complications are infusional reactions, which generally subside after the first 1-2 weeks of therapy, and prolonged lymphopenia associated with reactivation of viruses.
  • These can be minimized by careful monitoring and the use of prophylactic therapy.
  • Future studies will be directed toward: alternative routes (subcutaneous) and schedules of administration; use as first-line therapy; combination strategies with conventional chemotherapy; and use of alemtuzumab to purge minimal residual bone-marrow disease prior to SCT.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Mary Ann Liebert, Inc.
  • (PMID = 15453953.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 34
  •  go-up   go-down


10. Toro JR, Beaty M, Sorbara L, Turner ML, White J, Kingma DW, Raffeld M, Jaffe ES: gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol; 2000 Aug;136(8):1024-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study.
  • BACKGROUND: Only a few cases of primary gamma delta cutaneous T-cell lymphoma (CTCL) have been reported.
  • DESIGN: Patients were evaluated by clinical examination, and biopsy specimens of lesional skin were examined by light microscopy and immunohistochemistry.
  • Polymerase chain reaction amplification for T-cell receptor gamma gene rearrangements and in situ hybridization for EBV were performed on 3 biopsy specimens.
  • PATIENTS: Individuals with a clinical and histologic diagnosis of primary gamma delta CTCL.
  • OUTCOME MEASURES: Clinical, light microscopic, and immunohistochemical features, and the presence of T-cell rearrangement and EBV RNA in biopsy specimens.
  • Individuals exhibited an aggressive clinical course with resistance to multiagent chemotherapy and radiation.
  • All 3 cases exhibited an activated cytotoxic T-cell phenotype positive for T-cell intracellular antigen 1, perforin, and granzyme B.
  • A clonal T-cell receptor gamma chain gene rearrangement was detected in all 3 cases by polymerase chain reaction.
  • CONCLUSION: gamma delta Cutaneous T-cell lymphomas are EBV-negative lymphomas that express a mature cytotoxic phenotype and have an aggressive clinical behavior.
  • [MeSH-major] Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Herpesvirus 4, Human / isolation & purification. Lymphoma, T-Cell, Cutaneous / virology. RNA, Viral / isolation & purification. Receptors, Antigen, T-Cell, gamma-delta / genetics. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2000 Aug;136(8):1052-4 [10926743.001]
  • (PMID = 10926739.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Number-of-references] 42
  •  go-up   go-down


11. Magro CM, Seilstad KH, Porcu P, Morrison CD: Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol; 2006 Jul;126(1):14-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement.
  • Most cutaneous T-cell lymphomas are derived from mature postthymic T cells of the CD4 subtype.
  • Accurate categorization is critical because of the specificity of therapeutic regimens, including biologics.
  • A 65-year-old woman was seen in 2001 because of a thigh mass manifesting an unusual phenotype eventually categorized as a mature postthymic CD8+ T-cell lymphoma with CD10 and weak CD20 expression.
  • Molecular studies revealed T-cell receptor and heavy chain immunoglobulin rearrangement.
  • Her cutaneous disease progressed despite several cycles of chemotherapy and radiation therapy.
  • However, a therapeutic trial with denileukin diftitox resulted in a striking response.
  • The importance of this case lies in the novel phenotype and dual T- and B-cell rearrangements.
  • [MeSH-major] Antigens, CD / metabolism. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Immunoglobulin Heavy Chains / genetics. Lymphoma, T-Cell, Cutaneous / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Antigens, CD20 / metabolism. Antigens, CD8 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Genes, T-Cell Receptor beta / genetics. Humans. Immunophenotyping / methods. Neoplasm Recurrence, Local. Neprilysin / metabolism. Prednisolone / administration & dosage. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / pathology. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753590.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD8; 0 / Immunoglobulin Heavy Chains; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Lansigan F, Foss FM: Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs; 2010 Feb 12;70(3):273-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and emerging treatment strategies for cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphomas (CTCLs) are a rare group of mature T-cell lymphomas presenting primarily in the skin.
  • For the treating physician, the question of how to choose a particular therapy in the management of CTCL is important.
  • Other than an allogeneic stem cell transplant, there are no curative therapies for this disease.
  • Hence, many treatment modalities need to be offered to the patient over the course of their life.
  • An accepted treatment approach has been to delay traditional chemotherapy, which can cause excessive toxicity without durable benefit.
  • More conservative treatment strategies in the initial management of CTCL have led to the development of newer biological and targeted therapies.
  • These therapies include biological immune enhancers such as interferon alpha and extracorporeal photopheresis that exert their effect by stimulating an immune response to the tumour cells.
  • Lastly, systemic chemotherapy including transplantation is used when rapid disease control is needed or if all other biological therapies have failed.
  • As response rates to most of the biological agents used to treat CTCL are 25-30%, it is also reasonable to consider clinical trials with novel agents if one or two front-line therapies have failed, especially before considering chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Clinical Protocols. Drug Administration Routes. Hematopoietic Stem Cell Transplantation / methods. Humans

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):854-9 [17638728.001]
  • [Cites] Arch Dermatol. 1977 Oct;113(10):1387-9 [911166.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1379-81 [17459033.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Jul;7(1):51-8 [16879770.001]
  • [Cites] Blood. 1992 Aug 1;80(3):587-92 [1353380.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2007 Oct;23(5):163-71 [17803594.001]
  • [Cites] J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):238-45 [6609177.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):729-36 [1430395.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):521-5 [15286686.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Cancer. 1999 May 1;85(9):1985-95 [10223240.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2456-71 [11331325.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Arch Dermatol. 1999 Nov;135(11):1377-80 [10566837.001]
  • [Cites] Arch Dermatol. 1987 Jul;123(7):897-901 [3606168.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1027-35 [9276369.001]
  • [Cites] J Am Acad Dermatol. 2008 Oct;59(4):589-95 [18656282.001]
  • [Cites] J Am Acad Dermatol. 2002 Jan;46(1):95-106 [11756953.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):191-7 [12140464.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):624-31 [11552988.001]
  • [Cites] Hum Cell. 1995 Sep;8(3):121-6 [8652448.001]
  • [Cites] Br J Ophthalmol. 2006 Aug;90(8):1070-1 [16854841.001]
  • [Cites] Arch Dermatol. 1992 Jul;128(7):931-3 [1626959.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;941:1-11 [11594563.001]
  • [Cites] Blood. 1996 Feb 1;87(3):906-11 [8562961.001]
  • [Cites] J Clin Oncol. 1992 Dec;10 (12 ):1907-13 [1453206.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):987-95 [7607973.001]
  • [Cites] Yale J Biol Med. 1985 Nov-Dec;58(6):519-34 [3832664.001]
  • [Cites] Arch Dermatol. 1998 Aug;134(8):949-54 [9722724.001]
  • [Cites] Br J Dermatol. 2008 Apr;158(4):659-78 [18241274.001]
  • [Cites] Front Radiat Ther Oncol. 1991;25:80-9; discussion 132-3 [1908426.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):725-8 [445521.001]
  • [Cites] Blut. 1987 Apr;54(4):247-50 [3493819.001]
  • [Cites] J Am Acad Dermatol. 1989 Mar;20(3):416-28 [2537348.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1713-22 [17540844.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1014-30 [16574401.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:145-50 [3500880.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):993-1001 [12942567.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):807-13 [17052486.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3117-21 [10506607.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):250-6 [12950233.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):xvi-xvii [16354175.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):809-13 [2004959.001]
  • [Cites] Lancet. 1997 Jul 5;350(9070):32-3 [9217723.001]
  • [Cites] J Natl Cancer Inst. 1990 Aug 15;82(16):1353-5 [1696322.001]
  • [Cites] J Clin Oncol. 1987 Nov;5(11):1796-803 [3681368.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2437-41 [16216001.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2603-6 [10893292.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):287-99 [12120280.001]
  • [Cites] Ann Intern Med. 1984 Oct;101(4):484-7 [6332565.001]
  • [Cites] Blood. 2005 Jul 15;106(2):454-7 [15811959.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1368-76 [10506727.001]
  • [Cites] J Am Acad Dermatol. 1989 Mar;20(3):395-407 [2783939.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Blood. 1994 Aug 1;84(3):733-8 [7913841.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):960-7 [1607416.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1631-8 [15161670.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):1022-9 [8647968.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):54-60 [10863224.001]
  • [Cites] Dermatol Ther. 2003;16(4):311-21 [14686974.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):748-52 [10871938.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2929-39 [11929784.001]
  • [Cites] Blood. 2001 Jan 15;97(2):523-7 [11154232.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1176-8 [16172331.001]
  • [Cites] Ther Apher. 1999 Feb;3(1):50-62 [10079806.001]
  • [Cites] Oncology (Williston Park). 2007 Feb;21(2 Suppl 1):29-32 [17474357.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):325-32 [11902983.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1485-507 [14710899.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Jun;8(6):493-8 [17621880.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):69-73 [8682967.001]
  • (PMID = 20166766.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 90
  •  go-up   go-down


13. Horwitz SM: Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma; 2008 Dec;8 Suppl 5:S187-92
Hazardous Substances Data Bank. AMINOPTERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapies for cutaneous T-cell lymphomas.
  • Cutaneous T-cell lymphomas (CTCLs) are a group of uncommon mature T-cell lymphomas presenting primarily or exclusively in the skin.
  • The most common subtype, mycosis fungoides and its leukemic variant Sézary syndrome, frequently behave as a chronic lymphoma with good prognosis for early-stage disease and shortened survival only for patients in advanced stages.
  • Historically, these patients have experienced excessive toxicity from chemotherapy without durable benefit, leading to current conservative treatment strategies.
  • An increasing number of novel therapies are available or in development.
  • These newer therapies often have unique mechanisms of action and different toxicities with less myelosuppression than traditional cytotoxic chemotherapy.
  • Among these novel systemic therapies are so-called biologic therapies such as retinoids like bexarotene, the fusion toxin denileukin diftitox, lenalidomide, and toll-like receptor agonists.
  • Even agents considered to be conventional chemotherapy, such as gemcitabine or pegylated liposomal doxorubicin, have demonstrated activity in CTCL at relatively lower doses with less myelosuppression.
  • Evaluation through carefully designed clinical trials should lead to better, safer, and more effective treatment strategies in the future.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Aminopterin / analogs & derivatives. Aminopterin / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diphtheria Toxin / therapeutic use. Folic Acid Antagonists / therapeutic use. Histone Deacetylase Inhibitors. Humans. Interleukin-2 / therapeutic use. Photopheresis. Recombinant Fusion Proteins / therapeutic use. Skin Neoplasms / drug therapy. Tetrahydronaphthalenes / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073526.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Folic Acid Antagonists; 0 / Histone Deacetylase Inhibitors; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 25E79B5CTM / denileukin diftitox; A61RXM4375 / bexarotene; JYB41CTM2Q / Aminopterin
  • [Number-of-references] 44
  •  go-up   go-down


14. Murakami T, Ohtsuki M, Nakagawa H: Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile. Br J Dermatol; 2001 Apr;144(4):878-84
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile.
  • Angioimmunoblastic T-cell lymphoma is a type of peripheral T-cell lymphoma that is clinically characterized by high fever and generalized lymphadenopathy with or without cutaneous involvement.
  • Immunohistochemical studies indicated that the neoplastic cells were mature CD4+ T lymphocytes.
  • Southern blot analysis detected a clonal expansion of T-cell receptor beta.
  • Based on these findings, a diagnosis of angioimmunoblastic T-cell lymphoma with cutaneous infiltration was made.
  • Despite systemic chemotherapy, the disease exhibited a high level of activity and continued on a fatal course.
  • An analysis of gene expression profiling using complementary DNA microarrays revealed significant expression of some chemokines and cytokines, e.g. secondary lymphoid tissue chemokine, macrophage inflammatory protein (MIP)-1beta, MIP-3alpha, MIP-3beta, B-lymphocyte chemokine, interleukin-16 and tumour necrosis factor-beta, and an apoptosis-inhibitory protein (FLICE inhibitory protein) in the affected lymph nodes.
  • Profiling of gene expression patterns for a variety of genes in additional cases may be helpful in determining which factors predict the biological and clinical behaviour of angioimmunoblastic T-cell lymphoma or other aggressive malignant lymphomas.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298554.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


15. Klemke CD, Goerdt S: Molecular biology and targeted therapy of cutaneous T-cell lymphomas. G Ital Dermatol Venereol; 2008 Dec;143(6):365-74
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
  • Cutaneous T-cell lymphoma (CTCL) is an extra-nodal non-Hodgkin lymphoma of mature T cells.
  • These tumor cells home to and persist in the skin, producing a broad spectrum of clinical entities.
  • Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches.
  • Several clinical trials testing these targeted therapies have shown encouraging results.
  • This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. CD4-Positive T-Lymphocytes / immunology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antigens, Differentiation, T-Lymphocyte. Antigens, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis. Biomarkers, Tumor / immunology. Clinical Trials as Topic. Cytokines / immunology. Dendritic Cells / immunology. Diphtheria Toxin / therapeutic use. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylase Inhibitors. Humans. Hydroxamic Acids / therapeutic use. Interleukin-2 / therapeutic use. Keratinocytes / immunology. Macrophages / immunology. Mast Cells / immunology. Membrane Glycoproteins / immunology. NF-kappa B / immunology. Receptors, Chemokine / immunology. Recombinant Fusion Proteins / therapeutic use. Tetrahydronaphthalenes / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169209.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CTAGE1 protein, human; 0 / Cytokines; 0 / Diphtheria Toxin; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 0 / zanolimumab; 25E79B5CTM / denileukin diftitox; 3A189DH42V / alemtuzumab; 58IFB293JI / vorinostat; A61RXM4375 / bexarotene
  • [Number-of-references] 95
  •  go-up   go-down


16. Klemke CD, Goerdt S, Schrama D, Becker JC: New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges; 2006 May;4(5):395-406
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas.
  • Cutaneous T-cell lymphoma is an extra-nodal non-Hodgkin lymphoma of mature T cells.
  • These tumor cells home to and persist in the skin,producing a broad spectrum of clinical entities.
  • Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches.
  • Several clinical trials testing these targeted therapies have shown encouraging results.
  • This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / trends. Genetic Therapy / trends. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / physiopathology. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686607.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 90
  •  go-up   go-down


17. Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L: Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. Clin Lymphoma Myeloma; 2009 Oct;9(5):E21-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mycosis fungoides is the most common subtype of mature T-cell lymphoma that primarily arises in the skin.
  • In advanced tumor stage, chemotherapy is a second-line approach, which is generally not considered curative.
  • Initially, most patients profit from this treatment, but observed remissions usually do not exceed several months.
  • Because of possible immunosuppressive effects in vulnerable patients, the overall benefit of chemotherapy itself is not unequivocal in cutaneous T-cell lymphoma.
  • We report 3 patients whose tumor-stage mycosis fungoides was not sufficiently controlled by several preceding systemic therapies, including liposome-encapsulated doxorubicin.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858049.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Yoo EK, Cassin M, Lessin SR, Rook AH: Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol; 2001 Aug;45(2):208-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
  • BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is a clonally derived, skin-invasive malignancy of CD4(+) T lymphocytes with the phenotype of mature helper T cells.
  • Advancing stages of CTCL are associated with depressed cell-mediated immunity, increased production of T helper type 2 cytokines and decreased levels of T helper type 1 cytokines.
  • OBJECTIVE: Our purpose was to evaluate the cytokine secretion pattern and cell-mediated cytotoxicity in peripheral blood mononuclear cells of patients with Sézary syndrome in relation to the presence of the malignant clone.
  • METHODS: Serial polymerase chain reaction for the T-cell receptor-beta or T-cell receptor-gamma gene rearrangement was used to determine the presence of the malignant clone.
  • RESULTS: We demonstrate 3 cases of Sézary syndrome with typically suppressed cell-mediated cytotoxicity, elevated production of interleukin 4, and depressed production of interferon gamma by their peripheral blood mononuclear cells before institution of therapy with biologic response modifier therapy.
  • In all 3 cases after clinical and molecular remission, we observed striking immunologic changes, including an increase in levels of natural killer cell activity and interferon gamma production and decreased production of interleukin 4.
  • Moreover, the aberrant cytokine production may be the cause for suppression of cell-mediated immunity seen in advancing stages of CTCL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytotoxicity, Immunologic. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Interferon-gamma / biosynthesis. Interleukin-4 / biosynthesis. Killer Cells, Natural / immunology. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy. Th1 Cells / immunology
  • [MeSH-minor] Aged. Gene Rearrangement, T-Lymphocyte. Genes, T-Cell Receptor beta / genetics. Genes, T-Cell Receptor gamma / genetics. Humans. Male. Middle Aged. Photopheresis. Polymerase Chain Reaction. Recombinant Proteins. T-Lymphocyte Subsets

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2001 Aug;45(2):317 [11464201.001]
  • (PMID = 11464181.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


19. Stockfleth E, Ulrich C, Meyer T, Christophers E: Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res; 2002;160:251-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.
  • Transplantation of solid organs has been well established as a mode of therapy for the treatment of various end-stage organ diseases for many years.
  • Nowadays immunosuppressive therapies consist mainly in prednisolone, azathioprine, cyclosporine, anti-T-lymphocyte-globulin (ATG), anti-CD 3 antibody (OKT3) and substances of a new generation, such as tacrolimus or mycophenolic acid.
  • Chronically altered immune responsiveness is especially associated with a dramatically increased risk of malignancy, most frequently non-Hodgkin's lymphoma and skin cancer.
  • Within the first 5 years of immunosuppression 40% of transplant recipients experience premalignant skin tumors such as actinic keratoses and Bowen's disease, and also such skin cancers as squamous cell carcinomas and basal cell carcinomas.
  • The prevention of precancerous conditions and mature skin cancers in grafted patients includes protective clothing and adequate protection of UV-exposed skin regions, including lips, from sunlight with appropriate sunscreen.
  • Close dermatological surveillance through a specialized outpatient department should be ensured to detect potentially fatal skin malignancies at an early stage.
  • Early treatment of precancerous lesions includes topical retinoids, such as tretionin, tazarotene or adapalene.
  • The drug has been shown to have both antiviral and antitumor activity.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12079221.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


20. Bouwhuis SA, McEvoy MT, Davis MD: Sustained remission of Sézary syndrome. Eur J Dermatol; 2002 May-Jun;12(3):287-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma, is a devastating, highly symptomatic form of non-Hodgkin lymphoma.
  • Malignant clones of mature helper CD4 T cells containing large, convoluted nuclei known as Sézary cells circulate in the blood and infiltrate the skin.
  • Extracorporeal photopheresis, an immunomodulatory therapy, has become a primary therapy for these patients.
  • This pheresis-based therapy uses psoralen and ultraviolet A radiation-mediated photochemotherapy to induce immune responses.
  • [MeSH-major] Photopheresis. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Sezary syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11978575.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement